Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/27900
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMokbel, K-
dc.contributor.authorKodresko, A-
dc.contributor.authorGhazal, H-
dc.contributor.authorMokbel, R-
dc.contributor.authorTrembley, J-
dc.contributor.authorJouhara, H-
dc.date.accessioned2023-12-20T17:34:00Z-
dc.date.available2023-12-20T17:34:00Z-
dc.date.issued2023-08-26-
dc.identifierORCID iD: Alevtina Kodresko https://orcid.org/0009-0004-3434-3543-
dc.identifierORCID iD: Hussam Jouhara https://orcid.org/0000-0002-6910-6116-
dc.identifierORCID iD: Heba Ghazal https://orcid.org/0000-0002-1176-2241-
dc.identifier4272-
dc.identifier.citationMokbel, K. et al. (2023) 'The Evolving Role of Cryosurgery in Breast Cancer Management: A Comprehensive Review', Cancers, 15 (17), 4272, pp. 1 - 13. doi: 10.3390/cancers15174272.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/27900-
dc.description.abstractCopyright © 2023 by the authors. Breast cancer is the most commonly diagnosed type of cancer, accounting for approximately one in eight cancer diagnoses worldwide. In 2020, there were approximately 2.3 million new cases of breast cancer globally, resulting in around 685,000 deaths. Consequently, there is an ongoing need to develop innovative therapeutic approaches that can improve both clinical outcomes and patient quality of life. The use of ultra-low cryogenic temperatures, facilitated by cryogenic media such as liquid nitrogen, has revolutionized the biomedical field and opened up new possibilities for advanced clinical treatments, including cryosurgery. Cryosurgery has demonstrated its feasibility as a minimally invasive technique for destroying breast tumors and eliciting a significant antitumor immune response in the host. This feature sets cryosurgery apart from other ablative techniques. It has been shown to be well tolerated and effective, offering several advantages such as simplicity, the avoidance of general anesthesia, minimal pain, low morbidity, short recovery time, cost-effectiveness, and notably, improved aesthetic outcomes. The reviewed studies indicate that cryosurgery holds promise in the management of early-stage breast cancer and metastatic disease, especially in triple-negative and Her2-positive molecular subtypes in conjunction with checkpoint inhibitors and anti-Her2 antibodies, respectively. Furthermore, the effectiveness of cryosurgery in the management of ductal carcinoma in situ should be investigated as an alternative modality to surgery or surveillance. The minimally invasive nature of cryosurgery has the potential to significantly enhance the quality of life for patients.en_US
dc.description.sponsorshipAir Products PLC under grant agreement: 216-206-P-F.en_US
dc.format.extent1 - 13-
dc.format.mediumElectronic-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherMDPIen_US
dc.rightsCopyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectbreast canceren_US
dc.subjectcryogenic mediaen_US
dc.subjectcryosurgeryen_US
dc.subjectcryoablationen_US
dc.subjectnitrogenen_US
dc.titleThe Evolving Role of Cryosurgery in Breast Cancer Management: A Comprehensive Reviewen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/cancers15174272-
dc.relation.isPartOfCancers-
pubs.issue17-
pubs.publication-statusPublished online-
pubs.volume15-
dc.identifier.eissn2072-6694-
dc.rights.holderThe authors-
Appears in Collections:Dept of Mechanical and Aerospace Engineering Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).2.23 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons